Skip to main content
M

Mirna

Mirna develops precision veterinary diagnostics technology that enhances disease testing for companion animals, improving the accuracy and speed of diagnoses. Their NEMO Companion Animal Test addresses the need for better diagnostic tools in veterinary practices, ultimately leading to improved patient outcomes and client engagement.

Whitburn, United KingdomFounded 2019262K+ followers
Updated 20 months ago

Funding

$5.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

NC
Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current veterinary diagnostic methods often lack the sensitivity for early disease detection in companion and production animals, leading to delayed intervention and potentially poorer outcomes. Traditional diagnostic approaches may also be invasive or time-consuming, creating challenges for both veterinarians and animal owners.

Solution

MI:RNA Diagnostics develops precision veterinary diagnostics using microRNA (miRNA) biomarkers and artificial intelligence to improve early disease detection and monitoring in animals. Their technology analyzes blood samples to identify unique miRNA signatures associated with specific diseases, enabling earlier and more accurate diagnoses. By integrating miRNA analysis with AI-powered modeling, MI:RNA provides a comprehensive precision medicine approach that enhances diagnostic accuracy and supports proactive disease management. This innovative approach allows veterinarians to offer improved care, strengthen client engagement, and elevate their level of patient care through enhanced diagnostics and personalized treatment plans.

Target Audience

The primary target audience includes veterinary surgeons, veterinary practices, and animal health researchers focused on improving disease diagnosis and management in companion and production animals.

Features

  • Utilizes microRNA (miRNA) biomarkers for early and accurate disease detection
  • Employs artificial intelligence (AI) and machine learning for data interpretation and predictive modeling
  • Offers non-invasive blood sample analysis for companion and production animals
  • Provides diagnostic tools for Myxomatous Mitral Valve Disease (MMVD) in dogs
  • Supports early detection of Johne’s disease in livestock
  • Facilitates proactive disease management and personalized treatment plans
This profile is AI-generated and may contain inaccuracies.